EFFECT OF MELATONIN IN POST-STROKE RECOVERY
DOI:
https://doi.org/10.22159/ajpcr.2022.v15i4.43466Keywords:
Stroke, Melatonin, Modified rankin scale, Communication disability scale, Cognitive assessment of stroke patientsAbstract
Objective: Stroke is the second main cause of death worldwide. Recovery from a stroke differs from person to person. Melatonin is a neuroprotective agent with low adverse effects. The limitation of melatonin studies on human and other clinical bases made us keen to took up this research work to explore its full potential as a neuroprotective agent. The purpose of this research was to evaluate the effect of melatonin in stroke recovery inpatients.
Methods: This was a present prospective observational study carried out at the Department of Neurology of tertiary care hospital over 6 months. The patient data were collected through history interview and from the case sheets. Continuous variables were presented as the minimum, maximum, median, mean, and standard error of the mean (SEM). Categorical variables were presented as frequencies and percentages.
Results: A total of 80 patients were included in this study based on inclusion criteria. A significant difference was not found in the age and gender between the two study groups. There is a statistically significant difference in the percentage of improvement of modified Rankin Scale (mRS), Communication Disability Scale (CDS), and Cognitive Assessment of Stroke Patients (CASP) scores between the study groups.
Conclusion: Our study concluded that patients received melatonin along with first-line treatment which has shown better efficacy in treating post-recovery stroke patients when compared with patients received first-line treatment alone. Melatonin served as an excellent neuroprotectant in patients of acute ischemic stroke with improvement in the motor, speech, and cognitive functions.
Downloads
References
Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012;298:229-317. doi: 10.1016/B978-0-12-394309-5.00006-7, PMID 22878108
Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ Res 2017;120:472-95. doi: 10.1161/ CIRCRESAHA.116.308398, PMID 28154098
Coleman ER, Moudgal R, Lang K, Hyacinth HI, Awosika OO, Kissela BM, et al. Early rehabilitation after stroke: A narrative review. Curr Atheroscler Rep 2017;19:59. doi: 10.1007/s11883-017-0686-6, PMID 29116473
Dobkin BH. Clinical practice. Rehabilitation after stroke. N Engl J Med 2005;352:1677-84. doi: 10.1056/NEJMcp043511, PMID 15843670
Simić-Panić D, Bošković K, Milićević M, Rabi Žikić T, Cvjetković Bošnjak M, Tomašević-Todorović S, et al. The impact of comorbidity on rehabilitation outcome after ischemic stroke. Acta Clin Croat 2018;57:5-15. doi: 10.20471/acc.2018.57.01.01, PMID 30256006
Correa-Paz C, da Silva-Candal A, Polo E, Parcq J, Vivien D, Maysinger D, et al. New approaches in nanomedicine for ischemic stroke. Pharmaceutics 2021;13:757. doi: 10.3390/pharmaceutics13050757, PMID 34065179
Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 2010;8:228-42. doi: 10.2174/157015910792246155, PMID 21358973
Hu Y, Wang Z, Pan S, Zhang H, Fang M, Jiang H, et al. Melatonin protects against blood–brain barrier damage by inhibiting the TLR4/ NF-κB signaling pathway after LPS treatment in neonatal rats. Oncotarget 2017;8:31638-54. doi: 10.18632/oncotarget.15780, PMID 28404943
Clapp-Lilly KL, Smith MA, Perry G, Harris PL, Zhu X, Drew KL, et al. Melatonin exhibits antioxidant properties in a mouse brain slice model of excitotoxicity. Int J Circumpolar Health 2002;61:32-40. doi: 10.3402/ijch.v61i1.17403, PMID 12002945
Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: Implications for stroke clinical trials: A literature review and synthesis. Stroke 2007;38:1091-6. doi: 10.1161/01. STR.0000258355.23810.c6, PMID 17272767
Chue WL, Rose ML, Swinburn K. The reliability of the communication disability profile: A patient-reported outcome measure for aphasia. Aphasiology 2010;24:940-56. doi: 10.1080/02687030903490541
Rodrigues JC, Becker N, Beckenkamp CL, Miná CS, de Salles JF, Bandeira DR. Psychometric properties of cognitive screening for patients with cerebrovascular diseases A systematic review. Dement Neuropsychol 2019;13:31-43. doi: 10.1590/1980-57642018dn13- 010004, PMID 31073378
Kuriakose D, Xiao Z. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. Int J Mol Sci 2020;21:E7609. doi: 10.3390/ijms21207609, PMID 33076218
Rink C, Khanna S. Significance of brain tissue oxygenation and the arachidonic acid cascade in stroke. Antioxid Redox Signal 2011;14:1889-903. doi: 10.1089/ars.2010.3474, PMID 20673202
Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009;7:65-74. doi: 10.2174/157015909787602823, PMID 19721819
Kirdajova DB, Kriska J, Tureckova J, Anderova M. Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 2020;14:51.
Lee JG, Woo YS, Park SW, Seog DH, Seo MK, Bahk WM. The neuroprotective effects of melatonin: Possible role in the pathophysiology of neuropsychiatric disease. Brain Sci 2019;9:285.
Alghamdi BS. The neuroprotective role of melatonin in neurological disorders. J Neurosci Res 2018;96:1136-49.
Yousufuddin M, Young N. Aging and ischemic stroke. Aging (Albany NY) 2019;11:2542-4.
Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, et al. Sex differences in stroke: Epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol 2008;7:915-26.
Lin HW, Lee EJ. Effects of melatonin in experimental stroke models in acute, sub-acute, and chronic stages. Neuropsychiatry Dis Treat 2009;5:157-62.
Labban S, Alghamdi BS, Alshehri FS, Kurdi M. Effects of melatonin and resveratrol on recognition memory and passive avoidance performance in a mouse model of Alzheimer’s disease. Behav Brain Res 2021;402:113100.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Sara Shreen
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
